On Thursday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), BioTime, Inc. (NYSEMKT:BTX), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Organovo Holdings, Inc. (NYSEMKT:ONVO)

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), with shares inclined 7.23%, closed at $77.08.

BioTime, Inc. (NYSEMKT:BTX), with shares jumped 6.94%, settled at $4.78.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), with shares climbed 6.76%, and closed at $4.03.

Organovo Holdings, Inc. (NYSEMKT:ONVO), surged 6.68%, and closed at $4.47.

Latest NEWS regarding these Stocks are depicted underneath:

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)

Formerly on March 6, Isis Pharmaceuticals, Inc. (ISIS), declared that it has earned a $9 million milestone payment from Biogen Idec related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA).

ENDEAR, a Phase 3 study of ISIS-SMNRx, is a randomized, double-blind, sham-procedure controlled thirteen month study in about 110 infants diagnosed with SMA. The study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMNRx with a primary endpoint of survival or time to permanent ventilation. Additional efficacy endpoints are also comprised of in the study.

Isis is exploiting its leadership position in RNA-targeted technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline comprises of 38 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, counting neurological disorders, and cancer.

BioTime, Inc. (NYSEMKT:BTX)

Formerly on March 11, BioTime, Inc. (BTX), stated financial results for the quarter and year ended December 31, 2014, and highlighted its fourth quarter and recent corporate accomplishments.

Fourth Quarter and Recent Highlights:

BioTime, Inc.

• In November 2014, BioTime received authorization to start its Renevia™ pivotal clinical trial in HIV- associated lipoatrophy, a disorder that occurs in almost half of the about three million people on antiretroviral therapy in the U.S. and Europe. In the trial, Renevia™ is being tested as a delivery matrix for the patient’s own fat-derived cells and injected into portions of the patient’s face where there is lipoatrophy in order to promote facial tissue reconstruction. The first patient was treated in this trial in February 2015.
• In December 2014, BioTime strengthened its Board of Directors with the appointment of Angus C. Russell, former Chief Executive Officer of Shire plc, which is a leading global specialty biopharmaceutical corporation. The appointment of Mr. Russell followed the recent appointments to the board of Steve Cartt and Mike Mulroy, who were among the top executives of Questcor Pharmaceuticals.
• In December 2014, BioTime designated Adi Mohanty as Chief Operating Officer, bringing proven leadership in biopharmaceutical product development and commercialization to the corporation. Mr. Mohanty is a former executive of Shire with noteworthy experience in biopharmaceutical product development, manufacturing, and commercialization and a background in regenerative medicine.

Asterias Biotherapeutics, Inc.

In February 2015, Asterias raised $5.5 million through the sale of shares of its Series A ordinary stock.

In March 2015, Asterias Biotherapeutics (NYSE MKT: AST) initiated patient enrollment for its Phase 1/2a clinical trial of its product, AST-OPC1 (oligodendrocyte progenitor cells), in complete cervical spinal cord injury.

Cell Cure Neurosciences Ltd.

In October 2014, the U.S. Food and Drug Administration (FDA) cleared Cell Cure’s Investigational New Drug (IND) application to initiate the Phase 1/2a clinical trial of OpRegen® in patients with the severe form of age-related macular degeneration with geographic atrophy. In February 2015, the OpRegen® Phase 1/2a clinical trial opened at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is predictable to start shortly. OpRegen®comprises of high purity retinal pigment epithelial cells derived from human embryonic stem cells using a proprietary directed differentiation method.

BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage biotechnology corporation. BioTime and its auxiliaries are leveraging their industry-leading experience in pluripotent stem cell technology and a broad intellectual property portfolio to facilitate the development and use of cell-based therapies and gene marker-based molecular diagnostics for major diseases and degenerative conditions for which there presently are no cures.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals, Inc. (SGYP), stated its financial results and business update for the fourth quarter and the year ended December 31, 2014.

Recent Developments:

• On January 8, 2015 and January 29, 2015 we declared that we had accomplished patient enrollment in the first and second of two pivotal phase 3 trials, respectively, which are evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Each trial is a randomized, 12-week, double-blind, placebo-controlled phase 3 trial evaluating plecanatide, once-daily oral tablets, in about 1350 adult patients with CIC. We expect to release top-line data results from the first phase 3 CIC trial in the second quarter of 2015, and top-line results from the second phase 3 CIC trial in the third quarter of 2015. In the fourth quarter of this year, we plan to file our first new drug application (NDA) with the FDA for plecanatide to treat CIC.
• On December 18, 2014 we declared the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation (IBS-C).
• On November 19, 2014 we declared positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) contrast with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study’s primary endpoint and demonstrated statistically noteworthy improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period. SP-333 was safe and well tolerated at all doses.
• On November 3, 2014 we declared the closing of a private offering of $200 million aggregate principal amount of 7.50% Convertible Senior Notes (Notes) due 2019 (counting the full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 million aggregate principal amount of 7.50% Convertible Senior Notes due 2019). The Notes mature on November 1, 2019, unless earlier converted. The Notes are convertible, at any time, into shares of our ordinary stock at an initial conversion rate of 321.5434 shares per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of $3.11 per share. The net proceeds from this offering were about $187.3 million, after deducting estimated expenses and the initial purchasers’ discount.

Synergy is a biopharmaceutical corporation focused on the development of novel therapies to treat gastrointestinal (GI) diseases and disorders. The corporation’s proprietary platform technology is based on the naturally occurring human GI peptide – uroguanylin - a key to normal GI physiology. Synergy has created two unique analogs of uroguanylin - plecanatide and SP-333 – both designed to mimic uroguanylin’s natural activity and target a variety of GI conditions.

Organovo Holdings, Inc. (NYSEMKT:ONVO)

Formerly on March 13, Organovo Holdings, Inc. (ONVO), provided the following market update:

Organovo remains extremely excited about the early commercial success of our exVive3D™ Human Liver Tissue and we continue to believe it has a strong commercial future in front of it. Nothing has changed from the Corporation’s perspective, nor are we in possession of any new information that would dampen our optimism about the future of our exVive3D™ Human Liver Tissue or the future of Organovo. As we’ve said before, we believe that as we penetrate the toxicology market, our exVive3D™ Human Liver Tissue and service will grow into the tens of millions in annual proceed, and has $100M+ proceed potential in the future as we pursue diligent sales and marketing efforts (inside of a total addressable market of over $1B). We believe we’re on the way to building a strong profit center in research tissues for Organovo, which will expand with our launch of 3D bioprinted kidney tissues in 2016.

In addition to having excellent operational execution, Organovo is also financially strong. Our balance sheet is strong with no debt, more than $50 million in cash on hand, and a preceding quarter burn rate that annualized at about $19 million per year. We have recently communicated we expect spending on current projects to ramp our annual burn rate to $25 million per year; but even at that higher rate of spending, we have about two years of operating cash on hand.

Organovo’s Board and administration team are focused on executing our aims and remain confident in the Corporation’s technology and team. The Corporation has hit every milestone it has described to investors on a timely basis since going public in 2012. We are proud of our accomplishments to date, and we look forward to ongoing to execute our planned vision, counting a aim to build long-term shareholder value. We believe we are the leader in 3D bioprinting and 3D tissues and we are working diligently to retain leadership and capture value for our shareholders.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Corporation develops 3D human disease models through internal development and in partnership with pharmaceutical and academic partners.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.